Education
About Us
Working with TipRanks
Follow Us
Cognition Therapeutics (CGTX)
NASDAQ:CGTX
CGTX Stock Chart & Stats
$1.12
-$0.03(-3.56%)
At close: 4:00 PM EST
$1.12
-$0.03(-3.56%)
Day’s Range― - ―
52-Week Range$0.22 - $3.83
Previous CloseN/A
Volume950.02K
Average Volume (3M)2.91M
Market Cap
$98.87M
Enterprise Value$42.97M
Total Cash (Recent Filing)$39.82M
Total Debt (Recent Filing)$380.00K
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Apr 01, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding88,274,260
10 Day Avg. Volume2,171,776
30 Day Avg. Volume2,911,286
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)1.49
Price to Sales (P/S)0.00
P/FCF Ratio-0.98
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-704.41
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$3.00Price Target Upside167.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance SheetVery low reported debt provides structural financial flexibility versus many early-stage biotech peers, reducing near-term insolvency risk and giving management time to advance clinical programs. This durable strength helps sustain development activities while fundraising occurs.
Regulatory Engagement Advancing Phase 2bA formal FDA Type C meeting that clarified clinically meaningful endpoints materially reduces later-stage development execution risk. This durable regulatory progress strengthens the company’s path to a Phase 2b trial in DLB, improving likelihood of efficient trial design and regulator alignment.
Published Phase 2 Data For ZervimesinePeer-reviewed Phase 2 publication demonstrating safety and positive signals across behavioral, cognitive, functional, and movement domains provides durable scientific validation. This strengthens the biological rationale, de-risks later trials, and increases partnerability for out-licensing or collaborations.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this magnitude creates a structural reliance on external capital and compresses runway between financings. Over months this elevates execution risk for clinical programs unless burn is reduced or new non-dilutive funding is secured.
No Revenue; Widening LossesAbsence of commercial revenue and materially widening net losses reflect a business still in R&D spend mode. This structural lack of internal cash generation means long-term sustainability depends on future trial success or recurring outside funding, increasing investor and operational risk.
Reliance On Equity Financing / ATMFrequent use of at-the-market equity facilities signals ongoing dependence on dilutive equity raises to fund operations. Over time this increases shareholder dilution risk and can limit strategic optionality, making long-term funding costs and capital structure durability key concerns.
Cognition Therapeutics News
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.22 and its highest was $3.83 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Cognition Therapeutics’s market cap is $98.87M.
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 42 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.03.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 88,274,260 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went down -1.775%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Currently, no hedge funds are holding shares in CGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cognition Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (167.86% Upside)
$3.00 (167.86% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
291.01%
12-Months-Change
Fundamentals
Return on Equity
-109.73%
Trailing 12-Months
Asset Growth
-42.91%
Trailing 12-Months
Company Description
Cognition Therapeutics
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
CGTX Stock 12 Month Forecast
Average Price Target
$3.00
▲(167.86% Upside)
Technical Analysis
Tonix Pharma
―
Adicet Bio
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
17.66% Insiders
3.37% Mutual Funds
13.93% Other Institutional Investors
61.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---